Deficiency of Erbin induces resistance of cervical cancer cells to anoikis in a STAT3-dependent manner

Oncogenesis

Volumn 2, Issue , 2013, Pages

  Hu, Y ^a   Chen, H ^a   Duan, C ^b   Liu, D ^a   Qian, L ^a   Yang, Z ^a   Guo, L ^a   Song, L ^a   Yu, M ^a   Hu, M ^a   Shi, M ^a   Guo, N ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

anoikis; cervical cancer; Erbin; IL 6; metastasis; STAT3

Indexed keywords

CELL PROTEIN; ERBIN PROTEIN; INTERLEUKIN 6; JANUS KINASE 2 INHIBITOR; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; STAT3 PROTEIN; UNCLASSIFIED DRUG; WP 1066;

ANOIKIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER RESISTANCE; CELL SURVIVAL; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; TUMOR XENOGRAFT; UTERINE CERVIX CANCER;

MUS MUSCULUS;

EID: 84879974230     PISSN: None     EISSN: 21579024     Source Type: Journal    
DOI: 10.1038/oncsis.2013.18     Document Type: Article

References (57)

1. Bilder D, Birnbaum D, Borg JP, Bryant P, Huigbretse J, Jansen E et al. Collective nomenclature for LAP proteins. Nat Cell Biol 2000; 2: E114.
2. Bryant PJ, Huwe A. LAP proteins: what's up with epithelia? Nat Cell Biol 2000; 2: E141-E143.
3. Apperson ML, Moon IS, Kennedy MB. Characterization of densin-180, a new brainspecific synaptic protein of the O-sialoglycoprotein family. J Neurosci 1996; 16: 6839-6852. (Pubitemid 26359366)
4. Saito H, Santoni MJ, Arsanto JP, Jaulin-Bastard F, Le Bivic A, Marchetto S et al. Lano, a novel LAP protein directly connected to MAGUK proteins in epithelial cells. J Biol Chem 2001; 276: 32051-32055.
5. Borg JP, Marchetto S, Le Bivic A, Ollendorff V, Jaulin-Bastard F, Saito H et al. ERBIN: a basolateral PDZ protein that interacts with the mammalian ERBB2/HER2 receptor. Nat Cell Biol 2000; 2: 407-414.
6. Huang YZ, Wang Q, Xiong WC, Mei L. Erbin is a protein concentrated at postsynaptic membranes that interacts with PSD-95. J Biol Chem 2001; 276: 19318-19326.
7. Bilder D, Perrimon N. Localization of apical epithelial determinants by the basolateral PDZ protein Scribble. Nature 2000; 403: 676-680. (Pubitemid 30104011)
8. Izawa I, Nishizawa M, Tomono Y, Ohtakara K, Takahashi T, Inagaki M. ERBIN associates with p0071, an armadillo protein, at cell-cell junctions of epithelial cells. Genes Cells 2002; 7: 475-485. (Pubitemid 34537772)
9. Legouis R, Gansmuller A, Sookhareea S, Bosher JM, Baillie DL, Labouesse M. LET-413 is a basolateral protein required for the assembly of adherens junctions in Caenorhabditis elegans. Nat Cell Biol 2000; 2: 415-422.
10. Ellenbroek SI, Iden S, Collard JG. Cell polarity proteins and cancer. Semin Cancer Biol 2012; 22: 208-215.
11. Dan L, Shi M, Duan H, Han C, Guo N. Erbin, a negative regulator in diverse signal pathways. Curr Protein Pept Sci 2010; 11: 759-764.
12. Jaulin-Bastard F, Arsanto JP, Le Bivic A, Navarro C, Vely F, Saito H et al. Interaction between Erbin and a Catenin-related protein in epithelial cells. J Biol Chem 2002; 277: 2869-2875. (Pubitemid 34953320)
13. Kobe B, Kajava AV. The leucine-rich repeat as a protein recognition motif. Curr Opin Struct Biol 2001; 11: 725-732. (Pubitemid 34076634)
14. Fan JS, Zhang M. Signaling complex organization by PDZ domain proteins. Neurosignals 2002; 11: 315-321. (Pubitemid 37494386)
15. Harmon RM, Simpson CL, Johnson JL, Koetsier JL, Dubash AD, Najor NA et al. Desmoglein-1/Erbin interaction suppresses ERK activation to support epidermal differentiation. J Clin Invest 2013; 123: 1556-1570.
16. Dai P, Xiong WC, Mei L. Erbin inhibits RAF activation by disrupting the sur-8-Ras-Raf complex. J Biol Chem 2006; 281: 927-933.
17. Huang YZ, Zang M, Xiong WC, Luo Z, Mei L. Erbin suppresses the MAP kinase pathway. J Biol Chem 2003; 278: 1108-1114. (Pubitemid 36790791)
18. Rangwala R, Banine F, Borg JP, Sherman LS. Erbin regulates mitogen-activated protein (MAP) kinase activation and MAP kinase-dependent interactions between Merlin and adherens junction protein complexes in Schwann cells. J Biol Chem 2005; 280: 11790-11797. (Pubitemid 40418493)
19. Shi M, Zhao M, Hu M, Liu D, Cao H, Qian L et al. b2-AR-induced Her2 transactivation mediated by Erbin confers protection from apoptosis in cardiomyocytes. Int J Cardiol. (e-pub ahead of print 5 May 2012).
20. McDonald C, Chen FF, Ollendorff V, Ogura Y, Marchetto S, Lecine P et al. A role for Erbin in the regulation of Nod2-dependent NF-kappaB signaling. J Biol Chem 2005; 280: 40301-40309. (Pubitemid 41779167)
21. Kufer TA, Kremmer E, Banks DJ, Philpott DJ. Role for erbin in bacterial activation of Nod2. Infect Immun 2006; 74: 3115-3124. (Pubitemid 43794500)
22. Warner DR, Pisano MM, Roberts EA, Greene RM. Identification of three novel Smad binding proteins involved in cell polarity. FEBS Lett 2003; 539: 167-173. (Pubitemid 36351306)
23. Dai F, Chang C, Lin X, Dai P, Mei L, Feng XH. Erbin inhibits transforming growth factor beta signaling through a novel Smad-interacting domain. Mol Cell Biol 2007; 27: 6183-6194. (Pubitemid 47326705)
24. Martin-Belmonte F, Perez-Moreno M. Epithelial cell polarity, stem cells and cancer. Nat Rev Cancer 2012; 12: 23-38.
25. Pearson HB, Perez-Mancera PA, Dow LE, Ryan A, Tennstedt P, Bogani D et al. SCRIB expression is deregulated in human prostate cancer, and its deficiency in mice promotes prostate neoplasia. J Clin Invest 2011; 121: 4257-4267.
26. Wu M, Pastor-Pareja JC, Xu T. Interaction between Ras(V12) and scribbled clones induces tumour growth and invasion. Nature 2010; 463: 545-548.
27. Zhan L, Rosenberg A, Bergami KC, Yu M, Xuan Z, Jaffe AB et al. Deregulation of scribble promotes mammary tumorigenesis and reveals a role for cell polarity in carcinoma. Cell 2008; 135: 865-878.
28. Favre B, Fontao L, Koster J, Shafaatian R, Jaunin F, Saurat JH et al. The hemidesmosomal protein bullous pemphigoid antigen 1 and the integrin beta 4 subunit bind to ERBIN. Molecular cloning of multiple alternative splice variants of ERBIN and analysis of their tissue expression. J Biol Chem 2001; 276: 32427-32436.
29. Taddei ML, Giannoni E, Fiaschi T, Chiarugi P. Anoikis: an emerging hallmark in health and diseases. J Pathol 2012; 226: 380-393.
30. Guadamillas MC, Cerezo A, Del Pozo MA. Overcoming anoikis-pathways to anchorage-independent growth in cancer. J Cell Sci 2011; 124: 3189-3197.
31. Jenning S, Pham T, Ireland SK, Ruoslahti E, Biliran H. Bit1 in anoikis resistance and tumor metastasis. Cancer Lett 2013; 333: 147-151.
32. Simpson CD, Anyiwe K, Schimmer AD. Anoikis resistance and tumor metastasis. Cancer Lett 2008; 272: 177-185.
33. Du XL, Yang H, Liu SG, Luo ML, Hao JJ, Zhang Y et al. Calreticulin promotes cell motility and enhances resistance to anoikis through STAT3-CTTN-Akt pathway in esophageal squamous cell carcinoma. Oncogene 2009; 28: 3714-3722.
34. Fan Y, Zhang YL, Wu Y, Zhang W, Wang YH, Cheng ZM et al. Inhibition of signal transducer and activator of transcription 3 expression by RNA interference suppresses invasion through inducing anoikis in human colon cancer cells. World J Gastroenterol 2008; 14: 428-434. (Pubitemid 351320852)
35. Landen Jr. CN, Lin YG, Armaiz Pena GN, Das PD, Arevalo JM, Kamat AA et al. Neuroendocrine modulation of signal transducer and activator of transcription-3 in ovarian cancer. Cancer Res 2007; 67: 10389-10396. (Pubitemid 350070814)
36. Shi M, Liu D, Duan H, Qian L, Wang L, Niu L et al. The beta2-adrenergic receptor and Her2 comprise a positive feedback loop in human breast cancer cells. Breast Cancer Res Treat 2011; 125: 351-362.
37. Xiao Q, Qu K, Wang C, Kong Y, Liu C, Jiang D et al. HDGF-related protein-3 is required for anchorage-independent survival and chemoresistance in hepatocellular carcinomas. Gut 2012; 62: 440-451.
38. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009; 9: 798-809.
39. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007; 7: 41-51. (Pubitemid 46020826)
40. Endo TA, Masuhara M, Yokouchi M, Suzuki R, Sakamoto H, Mitsui K et al. A new protein containing an SH2 domain that inhibits JAK kinases. Nature 1997; 387: 921-924. (Pubitemid 27289595)
41. Naka T, Narazaki M, Hirata M, Matsumoto T, Minamoto S, Aono A et al. Structure and function of a new STAT-induced STAT inhibitor. Nature 1997; 387: 924-929. (Pubitemid 27289596)
42. Starr R, Willson TA, Viney EM, Murray LJ, Rayner JR, Jenkins BJ et al. A family of cytokine-inducible inhibitors of signalling. Nature 1997; 387: 917-921. (Pubitemid 27289594)
43. Stahl N, Farruggella TJ, Boulton TG, Zhong Z, Darnell Jr. JE, Yancopoulos GD. Choice of STATs and other substrates specified by modular tyrosine-based motifs in cytokine receptors. Science 1995; 267: 1349-1353.
44. Shukla S, Shishodia G, Mahata S, Hedau S, Pandey A, Bhambhani S et al. Aberrant expression and constitutive activation of STAT3 in cervical carcinogenesis: implications in high-risk human papillomavirus infection. Mol Cancer 2010; 9: 282.
45. Chen CL, Hsieh FC, Lieblein JC, Brown J, Chan C, Wallace JA et al. Stat3 activation in human endometrial and cervical cancers. Br J Cancer 2007; 96: 591-599.
46. Takemoto S, Ushijima K, Kawano K, Yamaguchi T, Terada A, Fujiyoshi N et al. Expression of activated signal transducer and activator of transcription-3 predicts poor prognosis in cervical squamous-cell carcinoma. Br J Cancer 2009; 101: 967-972.
47. Zhong Z, Wen Z, Darnell Jr. JE. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 1994; 264: 95-98. (Pubitemid 24144493)
48. Grandis JR, Drenning SD, Chakraborty A, Zhou MY, Zeng Q, Pitt AS et al. Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-mediated cell growth In vitro. J Clin Invest 1998; 102: 1385-1392. (Pubitemid 28467567)
49. Lo HW, Hsu SC, Ali-Seyed M, Gunduz M, Xia W, Wei Y et al. Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. Cancer Cell 2005; 7: 575-589. (Pubitemid 40799250)
50. Shi M, Liu D, Duan H, Han C, Wei B, Qian L et al. Catecholamine up-regulates MMP-7 expression by activating AP-1 and STAT3 in gastric cancer. Mol Cancer 2010; 9: 269.
51. Arredondo J, Chernyavsky AI, Jolkovsky DL, Pinkerton KE, Grando SA. Receptormediated tobacco toxicity: cooperation of the Ras/Raf-1/MEK1/ERK and JAK-2/STAT-3 pathways downstream of alpha7 nicotinic receptor in oral keratinocytes. FASEB J 2006; 20: 2093-2101. (Pubitemid 44953908)
52. Bard-Chapeau EA, Li S, Ding J, Zhang SS, Zhu HH, Princen F et al. Ptpn11/Shp2 acts as a tumor suppressor in hepatocellular carcinogenesis. Cancer Cell 2011; 19: 629-639.
53. Lesina M, Kurkowski MU, Ludes K, Rose-John S, Treiber M, Kloppel G et al. Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 2011; 19: 456-469.
54. Vultur A, Cao J, Arulanandam R, Turkson J, Jove R, Greer P et al. Cell-to-cell adhesion modulates Stat3 activity in normal and breast carcinoma cells. Oncogene 2004; 23: 2600-2616. (Pubitemid 38586314)
55. Elsum I, Yates L, Humbert PO, Richardson HE. The Scribble-Dlg-Lgl polarity module in development and cancer: from flies to man. Essays Biochem 2012; 53: 141-168.
56. Zhang H, Yu M, Hu M, Qian L, Chen L, Shi M et al. Overexpression, refolding, purification of Erbin PDZ domain from Escherichia coli and preparation of its polyclonal antibody. Prep Biochem Biotechnol 2008; 38: 282-293. (Pubitemid 351882226)
57. Zhou Q, Zeng R, Xu C, Liu L, Chen L, Kou P et al. Erbin inhibits TGF-beta1-induced EMT in renal tubular epithelial cells through an ERK-dependent pathway. J Mol Med (Berl) 2012; 90: 563-574.